-->

Tech Seeker (TS)

Ablynx
Profile last edited on: 3/17/2022

Subsidiary of biopharmaceutical company Sanofi engaged in the discovery and development of nanobodies
TS Type
Small firm: Foreign
Status
Year Founded
2001
Last Involved Year
2006

Key People / Management

Location Information

Park Zwijnaarde
Ghent, BG
   (800) 981-2491
   www.ablynx.com

Public Profile

Ablynx, a Sanofi company, is engaged in the development of Nanobodies®, proprietary therapeutic proteins based on single-domain antibody fragments, which combine the advantages of conventional antibody drugs with some of the features of small-molecule drugs. Nanobodies have potential uses in the treatment of a range of serious and life-threatening human diseases. Ablynx advances a portfolio of Nanobody-based therapeutic programs in several major disease areas, including inflammation, haematology, immuno-oncology and oncology. The acquisition of Ablynx (June 2018) continues Sanofi’s commitment to breakthrough innovation, focused on technologies addressing multiple disease targets with single multi-specific molecules. Sanofi is committed to accelerating Ablynx’s Nanobody development programmes

Extent of SBIR involvement

User Avatar

Synopsis: Techseeker Business Condition

Headquartered
Belgium
Employment
450
Revenue
N/A
Public/Private
Privately Held
Stock Info
---
Received SBIR $$
No

SBIR firms in the news

There are no news available.